These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35195819)

  • 1. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
    Germano IM; Ziu M; Wen P; Ormond DR; Olson JJ
    J Neurooncol; 2022 Jun; 158(2):225-253. PubMed ID: 35195819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
    Winograd E; Germano I; Wen P; Olson JJ; Ormond DR
    J Neurooncol; 2022 Jun; 158(2):265-321. PubMed ID: 34694567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults.
    Redjal N; Nahed BV; Dietrich J; Kalkanis SN; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):165-213. PubMed ID: 33215343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
    Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
    Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
    Saha D; Rabkin SD; Martuza RL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
    Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
    J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ; Fisher BJ; Bauman GS; Megyesi JF; Watling CJ; Macdonald DR
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
    Olson JJ; Nayak L; Ormond DR; Wen PY; Kalkanis SN;
    J Neurooncol; 2014 Jul; 118(3):501-55. PubMed ID: 24740194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.
    Morrow K; Sloan A; Olson JJ; Ormond DR
    J Neurooncol; 2024 Oct; ():. PubMed ID: 39400661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
    Yan W; Liu Y; Yang P; Wang Z; You Y; Jiang T
    Oncotarget; 2015 May; 6(13):11676-82. PubMed ID: 25869098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
    Blumenthal DT; Gorlia T; Gilbert MR; Kim MM; Burt Nabors L; Mason WP; Hegi ME; Zhang P; Golfinopoulos V; Perry JR; Hyun Nam D; Erridge SC; Corn BW; Mirimanoff RO; Brown PD; Baumert BG; Mehta MP; van den Bent MJ; Reardon DA; Weller M; Stupp R
    Neuro Oncol; 2017 Aug; 19(8):1119-1126. PubMed ID: 28371907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.
    Ziu M; Kalkanis SN; Gilbert M; Ryken TC; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):585-607. PubMed ID: 26530261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    Ziu M; Kim BYS; Jiang W; Ryken T; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):215-267. PubMed ID: 33215344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.